Qualigen Therapeutics’ pancreatic cancer treatment was granted orphan designation by the FDA, according to a post to the agency’s website. Reference Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on QLGN:
- Qualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302, a G-Quadruplex (G4) Transcription Inhibitor for the Intended Indication of Pancreatic Cancer
- Qualigen Therapeutics provides update on developments at NanoSynex
- Qualigen Therapeutics Provides Update on Developments at NanoSynex; Significant Progress Reported on Infectious Disease Diagnostic Platform
- Qualigen Therapeutics regains compliance with Nasdaq minimum bid price rule
- Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule